Kingsbarn Private Equity focuses on
supporting buyouts in the lower-middle
market that are being led by management
teams and independent sponsors. Our goal
is to help support ownership transitions by
providing the hard-to-find equity required to
meet the selling owner's needs.
Kingsbarn is committed to transparency,
integrity, and delivering exceptional value to
our investors.
Larger businesses (greater than $5M EBITDA) typically trade at higher multiples which reduces the return profile to investors.
Acquisition multiples for companies under $5mm EBITDA are much lower, providing multiple arbitrage opportunity when EBITDA growth is achieved.
This creates a form of double return for investors - increase in profits and higher exit multiple - significantly increasing the IRR.
Easily implemented systems and processes that immediately create unrealized value in a small business.
Acquisition multiples for companies under $5mm EBITDA are much lower, providing multiple arbitrage opportunity when EBITDA growth is achieved.
This creates a form of double return for investors - increase in profits and higher exit multiple - significantly increasing the IRR.
Kingsbarn Private Equity closed the OMS, LLC, in June 2022 as a leveraged ownership buyout of one of the two principals of the company.
The unique structure put forth by Kingsbarn allows OMS, LLC, to pay back the funds provided prior to the ownership conversion with various financial requirements and stipulations.
Since the transaction was consummated, OMS has exceeded forecasted revenue and profit metrics and has gained contracts that will likely double the company's revenue by 2025.
OMS Group is a leading supplier of both manufactured assemblies and custom electric motors for clients across North America and Asia.
Advanced Radiotherapy Technologies ("ART") develops turnkey, freestanding radiotherapy centers for the use of physician practices and hospitals. ART has combined decades of experience in the development of superior radiotherapy centers to provide our clinical partners the best cancer care solutions for their patients.
ART's centers feature state-of-the-art radiotherapy equipment, such as, but not limited to, the RefleXion X-1, SOMATOM® go. platform, Varian Edge, and Somatom go.Pro. Our delivery includes financing, design, engineering, construction, equipment installation and clinical acceptance leading to first patient treatment. ART is currently seeking qualified clinical partners to integrate our cancer centers into their existing cancer care services.
ART is a joint venture formed by Integrated Proton Solutions ("IPS") and Kingsbarn Realty Capital ("KB").